




# Improved Survival with Interferon Alpha Maintenance Therapy Following Pleurectomy / Decortication and Radiation for Malignant Pleural Mesothelioma



Robert B. Cameron, M.D.  
Shahriyour Andaz, M.D.  
Michael T. Selch, M.D.  
Michael C. Fishbein, M.D.  
Division of Thoracic Surgery



David Geffen School of Medicine at UCLA



# Mesothelioma: Summary

- Median survival for all patients: 13.8 mos
- Median survival for patient completing surgery and radiation: 17.0 months
- Median survival for patients receiving interferon alpha: 37 months
- 2 yr survival for stage I/II patients receiving interferon alpha: 80%

# Mesothelioma: Conclusions

- The treatment of MPM remains challenging
- Rational therapy with P/D and adjuvant radiation may produce similar results to more radical “trimodality” therapy (including EPP)
- “Maintenance” therapies may have a role in the treatment of MPM
- IFN as maintenance therapy may provide a survival benefit
- Randomized prospective trials are needed instead of continued reports of “institutional” experiences
- Novel treatments are still desperately needed

# Mesothelioma: UCLA Approach

